Literature DB >> 27632409

Progressive Myoclonus Epilepsy in Congenital Generalized Lipodystrophy type 2: Report of 3 cases and literature review.

Roberta Opri1, Gian Maria Fabrizi2, Gaetano Cantalupo3, Moreno Ferrarini2, Alessandro Simonati4, Bernardo Dalla Bernardina3, Francesca Darra3.   

Abstract

PURPOSE: A small case series with a neurodegenerative disorder involving central nervous system and related to Seipin mutations was recently reported. Herein we describe clinical and EEG features of three patients presenting with Progressive Myoclonus Epilepsy (PME) and Congenital Generalized Lipodystrophy type 2 (CGL2) related to novel Seipin mutations.
METHODS: The EEG-clinical picture was evaluated at epilepsy onset and in the follow-up period. The molecular analysis of BSCL2, Laforin and Malin genes was performed to patients and/or their parents by Denaturing High Performance Liquid Chromatography and automated nucleotide sequencing. Skin specimens collected from a patient were processed for histochemical and ultrastructural analysis.
RESULTS: The CGL2-PME syndrome co-segregated with two different BSCL2 genotypes: the homozygosity for c.782_783dupG involving exon 8 (two cases), or the compound heterozygosity for c.782_783dupG/c.828_829delAA (one case). Periodic-Acid Schiff positive osmiophilic material in the cytoplasm of fibrocytes and eccrine-gland cells were found in skin specimens. The lack of Lafora's bodies in skin specimens and the molecular analysis excluding mutations in Laforin and Malin genes ruled out Lafora disease.
CONCLUSION: The spectrum of CGL2 associated to BSCL2 gene mutations may include PMEs. Selected mutations in BSCL2 gene seem to be related to PMEs in patients with CGL2 phenotype.
Copyright © 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BSCL2; Berardinelli–Seip; EEG; Seipin

Mesh:

Substances:

Year:  2016        PMID: 27632409     DOI: 10.1016/j.seizure.2016.08.008

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  6 in total

1.  [A case report of congenital generalized lipodystrophy].

Authors:  Rui Liu; Hui-Jun Tan; Jia-Jia Liu; Yuan-Zong Song
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2018-10

2.  Focus on progressive myoclonic epilepsy in Berardinelli-Seip syndrome.

Authors:  Silvia Ferranti; Caterina Lo Rizzo; Alessandra Renieri; Paolo Galluzzi; Salvatore Grosso
Journal:  Neurol Sci       Date:  2020-05-21       Impact factor: 3.307

3.  Celia's encephalopathy and c.974dupG in BSCL2 gene: a hidden change in a known variant.

Authors:  Sofía Sánchez-Iglesias; Melissa Crocker; Mar O'Callaghan; Alejandra Darling; Angels García-Cazorla; Rosario Domingo-Jiménez; Ana Castro; Antía Fernández-Pombo; Álvaro Ruibal; Pablo Aguiar; Miguel Garrido-Pumar; Antonio Rodríguez-Núñez; Julián Álvarez-Escudero; Rebecca J Brown; David Araújo-Vilar
Journal:  Neurogenetics       Date:  2019-03-23       Impact factor: 2.660

4.  Medical management of a child with congenital generalized lipodystrophy accompanied with progressive myoclonic epilepsy: A case report.

Authors:  Yi Zhang; Xiaofei Chen; Feixiang Luo; Lihua Jiang; Jialu Xu; Shuohui Chen
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

5.  Genotype-phenotype correlations of Berardinelli-Seip congenital lipodystrophy and novel candidate genes prediction.

Authors:  Meng Ren; Jingru Shi; Jinmeng Jia; Yongli Guo; Xin Ni; Tieliu Shi
Journal:  Orphanet J Rare Dis       Date:  2020-04-29       Impact factor: 4.123

6.  Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report.

Authors:  Stefania Pedicelli; Luca de Palma; Caterina Pelosini; Marco Cappa
Journal:  Ital J Pediatr       Date:  2020-10-24       Impact factor: 2.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.